Empagliflozin-induced liver injury
Drug-induced liver injury is a diagnosis of exclusion. Clinicians must rule out other causes, especially biliary obstruction, and use structured causality assessment tools to identify the offending drug.Empagliflozin and other sodium-glucose cotransporter 2 inhibitors can, in rare cases, cause liver injury. Monitoring liver function after initiating these drugs is advisable, particularly in patients with pre-existing liver disease.There is no specific treatment for idiosyncratic drug-induced liver injury. Prompt withdrawal of the offending and supportive care are usually sufficient for recovery.
Authors
- Mariana Dias (ORCID: https://orcid.org/0000-0002-7561-9014)
- Inês Parreira (ORCID: https://orcid.org/0000-0003-2017-2697)
- João Madeira Lopes (ORCID: https://orcid.org/0000-0002-1194-4483)
- Hélder Diogo Gonçalves (ORCID: https://orcid.org/0000-0003-4908-2986)
- Leila Duarte (ORCID: https://orcid.org/0000-0001-5202-3034)
- Ana Melício (ORCID: https://orcid.org/0009-0003-5386-6684)
- Sara Vasconcelos-Teixeira (ORCID: https://orcid.org/0009-0003-9164-7319)
Institutions
- Administração Regional de Saúde de Lisboa e Vale do Tejo (PT)
- Hospital de Santa Maria (PT)
Publication Details
- Journal
- European Journal of Case Reports in Internal Medicine
- Published
- 2025-12-03
- DOI
- https://doi.org/10.12890/2025_005889
- Citations
- 1
- Primary Topic
- Drug-Induced Hepatotoxicity and Protection
- Type
- article
- Field-Weighted Citation Impact
- 1.56